Immunogenicity of the ChAdOx1 nCoV-19 vaccine in patients with hematologic malignancies.
COVID-19 vaccine
COVID-19 virus
ChAdOx1 nCoV-19 vaccine
SARS-CoV-2 virus
Journal
Clinical and experimental vaccine research
ISSN: 2287-3651
Titre abrégé: Clin Exp Vaccine Res
Pays: Korea (South)
ID NLM: 101592344
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
06
08
2022
revised:
19
01
2023
accepted:
31
03
2023
medline:
22
5
2023
pubmed:
22
5
2023
entrez:
22
5
2023
Statut:
ppublish
Résumé
The present study aimed to study the immunogenicity of the ChAdOx1 nCoV-19 vaccine in patients with hematologic malignancies. This prospective cohort study of hematology patients aimed to evaluate their antibody levels against the receptor-binding domain of the severe acute respiratory syndrome coronavirus 2 spike protein and seroconversion rates following two doses of the ChAdOx1 nCoV-19 vaccine. Between June and July 2021, we enrolled 61 patients and included 44 patients in our analysis. Antibody levels were assessed 8 and 4 weeks after the first and second injections, respectively, and compared with those of a healthy group. Eight weeks after the first dose, the geometric mean antibody level was 1.02 binding antibody units (BAU)/mL in the patient group and 37.91 BAU/mL in the healthy volunteer group (p<0.01). Four weeks after the second dose, the geometric mean antibody level was 9.44 BAU/mL in patients and 641.6 BAU/mL in healthy volunteers (p<0.01). The seroconversion rates 8 weeks after the first dose were 27.27% and 98.86% in the patient and healthy volunteer groups, respectively (p<0.001). The seroconversion rate 4 weeks after the second dose was 47.73% in patients and 100% in healthy volunteers. Factors leading to lower seroconversion rates were rituximab therapy (p=0.002), steroid therapy (p<0.001), and ongoing chemotherapy (p=0.048). Factors that decreased antibody levels were hematologic cancer (p<0.001), ongoing chemotherapy (p=0.004), rituximab (p<0.001), steroid use (p<0.001), and absolute lymphocyte count <1,000/mm Immune responses were impaired in individuals with hematologic malignancies, particularly patients undergoing ongoing therapy and B-cell-depleting therapy. Additional vaccinations should be considered for these patients, and further investigated.
Identifiants
pubmed: 37214149
doi: 10.7774/cevr.2023.12.2.107
pmc: PMC10193112
doi:
Types de publication
Journal Article
Langues
eng
Pagination
107-115Informations de copyright
© Korean Vaccine Society.
Déclaration de conflit d'intérêts
No potential conflict of interest relevant to this article was reported.
Références
Blood Cancer J. 2021 Aug 10;11(8):142
pubmed: 34376633
Cancer Cell. 2021 Aug 9;39(8):1091-1098.e2
pubmed: 34214473
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
J Clin Virol. 2021 Jun;139:104820
pubmed: 33865031
JAMA Oncol. 2021 Nov 1;7(11):1714-1716
pubmed: 34379085
Open Forum Infect Dis. 2021 Jun 30;8(7):ofab353
pubmed: 34337100
Lancet. 2021 Apr 10;397(10282):1347-1348
pubmed: 33770519
J Clin Oncol. 2022 Jan 1;40(1):12-23
pubmed: 34752147
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
N Engl J Med. 2021 Dec 16;385(25):2348-2360
pubmed: 34587382
Blood Adv. 2022 Apr 12;6(7):2014-2034
pubmed: 34852173
Cancer Cell. 2021 Aug 9;39(8):1031-1033
pubmed: 34331856
J Hematol Oncol. 2021 Oct 14;14(1):168
pubmed: 34649563
Cancer Cell. 2021 Aug 9;39(8):1081-1090.e2
pubmed: 34133951